Conditional survival in breast cancer up to 10 years in the Nordic countries
Cancer Medicine · 2023
DOI: 10.1002/cam4.6436 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Frantisek Zitricky und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Center, Faculty of Medicine, Charles University Pilsen, Pilsen, Czech Republic. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Horizon 2020 Framework Programme.
Abstract (Originalsprache)
Background
Survival in breast cancer (BC) has developed favorably but late recurrences are still a problem.
Methods
We model survival data from the NORDCAN database and analyze 1‐, 5‐, and 10‐year relative survival and 5/1‐ and 10/5‐year conditional survival in BC from Denmark (DK), Finland (FI), Norway (NO), and Sweden (SE) between 1971 and 2020. Conditional survival measures survival in those who had survived year 1 to reach year 5 (5/1), or in those who had survived year 5 to reach year 10 (10/5).
Results
Almost all survival metrics were best for SE but survival in all countries improved in the course of time approaching the SE levels which were 98.3% for 1‐year, 92.3% for 5‐year, and 87.8% for 10‐year survival. Conditional 10/5‐year survival, covering 5 years, was better than 5/1‐year survival, covering 4 years. A contributing factor is most likely the high rate of recurrence in period 2–5 years. The difference was observed for all countries but for DK 10/5‐year survival approached 1‐year survival and for NO and SE 10/5‐year survival was only barely better than 5/1‐year survival. The explanation to this was the excellent 10/5‐year survival in DK compared to SE and particularly to NO. Literature search suggested that the reason for the relatively low 10/5‐year survival in NO might be stagnant survival development in old patients.
Conclusions
We assume that late mortality is critically limiting survival in BC and either interference with the late metastatic process or effective treatment will be key to future improvements in BC survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biomedical Center, Faculty of Medicine, Charles University Pilsen, Pilsen, Czech Republic.
- Hopp Children's Cancer Center (KiTZ), Heidelberg, Germany.
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
- Cancer Gene Therapy Group, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
- Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland.
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany.
ORCID-Profile: Akseli Hemminki, Kari Hemminki
Förderung
- Horizon 2020 Framework Programme
Zitieren
APA
Zitricky, F., Försti, A., Hemminki, A., & Hemminki, K. (2023). Conditional survival in breast cancer up to 10 years in the Nordic countries. Cancer Medicine. https://doi.org/10.1002/cam4.6436
Vancouver
Zitricky F, Försti A, Hemminki A, Hemminki K. Conditional survival in breast cancer up to 10 years in the Nordic countries. Cancer Medicine. 2023. doi:10.1002/cam4.6436
BibTeX
@article{Zitricky2023,
author = {Zitricky, Frantisek and Försti, Asta and Hemminki, Akseli and Hemminki, Kari},
title = {Conditional survival in breast cancer up to 10 years in the Nordic countries},
journal = {Cancer Medicine},
year = {2023},
doi = {10.1002/cam4.6436}
}
EUVIMED